At Pacegenix, we are pioneering precision cardiology
therapeutics to transform the treatment of heart rhythm
disorders.
Our mission is to improve patient outcomes and quality of life in the most debilitating arrhythmias, offering safe and efficacious therapies that improve lives. Pacegenix is committed to expanding indications and redefining the future of heart health with cutting-edge science and patient-focused innovation.
Innovative solution for Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation, aiming to develop a safe and efficacious treatment for this area of high unmet clinical need.
Atrial Fibrillation in Hypertrophic Cardiomyopathy (AF-HCM) is a unique clinical entity that is distinct from AF in the general population. AF-HCM has unique pathophysiology and is associated with higher risk of adverse clinical outcomes. Moreover, the traditional anti-arrhythmic drugs that are typically used for AFin general populations are either contraindicated or inadequate for use in AF-HCM, which highlights a significant unmet clinical need.
PACE-101 is a novel therapeutic being developed to be the first approved therapy to treat AF-HCM.
Improving treatment for patients with inappropriate rapid heart rate such as tachycardia in patients with heart failure, Inappropriate Sinus Tachycardia (IST), and other neurocardiac related arrythmias.
Inappropriate tachycardia, including conditions like tachycardia in heart failure Inappropriate Sinus Tachycardia (IST), and neurocardiac arrhythmias, impairs quality of life and increases morbidity. Current treatments often lack selectivity, reducing heart rate but risking compromised cardiac contractility or worsened heart failure symptoms. Pacegenix addresses this gap with PACE-201, a novel chronotropic agent targeting heart rate regulation pathways. Designed for conditions like IST and heart failure-associated tachycardia, PACE-201 aims to enhance precision medicine by lowering heart rate effectively while minimizing adverse effects on myocardial function, improving patient outcomes.
